You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
生物科技Structure Therapeutics減肥藥數據佳 股價飆逾30%
生物科技公司Structure Therapeutics(GPCR.US)實驗性減肥藥在一項小型早期試驗中取得成功,該股周五急升超過30%。 據Structure發布的新聞稿稱,每日一次的實驗性減肥藥,採用四星期後,幫助超重或肥胖的參與者平均減輕10磅的體重,並計劃在兩項較長的中期試驗中,測試其藥物作為糖尿病和肥胖症的治療方法。 Structure的藥丸與諾和Novo Nordisk(NVO.US)糖尿病藥物Ozempic和減肥藥Wegovy屬於同一類藥物。 多間藥廠正試圖加入蓬勃發展的肥胖藥物產業,分析師表示,至本世紀末,該產業全球市場或達到1,000億美元。 Structure的藥物或可與禮來(LLY.US)、Novo Nordisk及輝瑞(PFE.US)旗下口服肥胖藥物競爭,但該類藥物仍未在美國獲得批准。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account